CN106661549B - 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用 - Google Patents

抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用 Download PDF

Info

Publication number
CN106661549B
CN106661549B CN201580037524.0A CN201580037524A CN106661549B CN 106661549 B CN106661549 B CN 106661549B CN 201580037524 A CN201580037524 A CN 201580037524A CN 106661549 B CN106661549 B CN 106661549B
Authority
CN
China
Prior art keywords
alkyl
tert
group
benzyl
trimethylsilyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580037524.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106661549A (zh
Inventor
A·M·J·夏皮罗
L·G·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROTOKINETIX Inc
Original Assignee
PROTOKINETIX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROTOKINETIX Inc filed Critical PROTOKINETIX Inc
Publication of CN106661549A publication Critical patent/CN106661549A/zh
Application granted granted Critical
Publication of CN106661549B publication Critical patent/CN106661549B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201580037524.0A 2014-06-04 2015-06-02 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用 Active CN106661549B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007626P 2014-06-04 2014-06-04
US62/007,626 2014-06-04
PCT/CA2015/050509 WO2015184544A1 (en) 2014-06-04 2015-06-02 Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome

Publications (2)

Publication Number Publication Date
CN106661549A CN106661549A (zh) 2017-05-10
CN106661549B true CN106661549B (zh) 2022-02-11

Family

ID=54765902

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580037524.0A Active CN106661549B (zh) 2014-06-04 2015-06-02 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用

Country Status (8)

Country Link
US (5) US20150352155A1 (https=)
EP (1) EP3152297A4 (https=)
JP (1) JP6801934B2 (https=)
KR (1) KR102411834B1 (https=)
CN (1) CN106661549B (https=)
AU (1) AU2015271608B9 (https=)
NZ (1) NZ727749A (https=)
WO (1) WO2015184544A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011449A1 (en) 2016-01-27 2017-08-03 Protokinetix Inc. Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells
CA3012837A1 (en) 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
WO2021146812A1 (en) * 2020-01-24 2021-07-29 Protokinetix Inc. Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
WO2021179081A1 (en) * 2020-03-10 2021-09-16 Protokinetix Inc. Use of anti-aging glycopeptides for treatment of dry eye disease, retinal degenerative diseases, or occular inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878851B1 (fr) * 2004-12-02 2007-02-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation en cryochirurgie et/ou cryopreservation
FR2900656A1 (fr) * 2006-05-03 2007-11-09 Inst Nat Sciences Appliq Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAGPsTM – Anti-Aging Glyco Peptides;ProtoKinetix;《https://www.protokinetix.com/pdf/aagp-presentation-march-2010.pdf》;20100331;第29页 *

Also Published As

Publication number Publication date
EP3152297A1 (en) 2017-04-12
US12521419B2 (en) 2026-01-13
US20210023142A1 (en) 2021-01-28
US20150352155A1 (en) 2015-12-10
US20230414675A1 (en) 2023-12-28
EP3152297A4 (en) 2018-01-31
AU2015271608A1 (en) 2017-01-12
CN106661549A (zh) 2017-05-10
US20260102436A1 (en) 2026-04-16
AU2015271608B2 (en) 2021-05-27
WO2015184544A1 (en) 2015-12-10
US20170360844A1 (en) 2017-12-21
AU2015271608B9 (en) 2021-06-17
CA2950963A1 (en) 2015-12-10
NZ727749A (en) 2023-04-28
JP6801934B2 (ja) 2020-12-16
JP2017520275A (ja) 2017-07-27
KR102411834B1 (ko) 2022-06-21
KR20170023029A (ko) 2017-03-02

Similar Documents

Publication Publication Date Title
US12521419B2 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
ES2727030T3 (es) Composición farmacéutica para prevenir o tratar enfermedades inmunitarias o enfermedades inflamatorias, que contiene células madre tratadas con agonista de NOD2 o un producto cultivado del mismo
KR101973284B1 (ko) 신생아 ｈｉｅ 치료용 조성물
JP2016515571A (ja) 調節性ｔ細胞への分化を誘導し、及び増殖を促進することにより免疫反応を抑制するための医薬組成物
JP2024081763A (ja) 膵臓移植のファシリテーターとして繊維芽細胞を用いる１型糖尿病の治療方法および組成物
US11826387B2 (en) Use of anti-aging glycoprotein for enhancing survival of neurosensory precursor cells
CN1729010A (zh) 美拉加群在制造治疗i型糖尿病的药物中的用途
WO2017209270A1 (ja) ２５－ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
CA2950963C (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
US20040033946A1 (en) Cell damage inhibitor
HK1237814B (zh) 抗衰老糖肽在增强胰腺细胞健康、存活以及改善移植效果的应用
US20230142705A1 (en) Use of anti-aging glycopeptides for inhibition of immune rejection of a graft
HK1237814A1 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome
US20080139462A1 (en) Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CN114599379A (zh) 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法
JP2016138087A (ja) 抗腫瘍剤
Cheng Cellular Therapeutics-Based Strategies for Inducing Donor-Specific Tolerance to Vascularized Composite Allotransplants
KR20130072387A (ko) 면역 억제용 약학적 조성물
CN103896812A (zh) N，n’－二环己基－n－高级脂肪酸酰脲类似物及其制药用途
JP2012025673A (ja) Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237814

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant